Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group

Désirée Larenas-Linnemann1,2 • Jorge Luna-Pech3 • Elsy M. Navarrete-Rodríguez4 • Noel Rodríguez-Pérez5 • Alfredo Arias-Cruz6 • María Virginia Blandón-Vijil7 • Blanca E. Del Rio-Navarro4 • Alan Estrada-Cardona8 • Ernesto Onuma-Takane7 • Cesar Fireth Pozo-Beltrán9 • Adriana María Valencia-Herrera10 • Francisco Ignacio Ortiz-Aldana11 • Mirna Eréndira Toledo-Bahena10

Accepted: 12 November 2020 / Published online: 25 February 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021

Abstract
Purpose of Review At the juncture of the COVID-19 pandemic, the world is currently in an early phase of collecting clinical data and reports of its skin manifestations, and its pathophysiology is still highly conjectural. We reviewed cutaneous manifestations associated with COVID-19 in the pediatric age group.
Recent Findings Children infected by SARS-CoV-2 usually develop milder respiratory symptoms, but cutaneous manifestations seem a little more prevalent than in adults. These skin features of infection by the coronavirus can be similar to those produced by other common viruses, but there are also reports of cases with more heterogeneous clinical pictures, which have made their classification difficult. To date, the more frequently reported skin variants featured in pediatric cases are purpuric (pseudo-chilblain, necrotic-acral ischemia, hemorrhagic macules, and/or cutaneous necrosis), morbilliform/maculopapular, erythema multiforme, urticarial, vesicular, Kawasaki-like, and miscellaneous (highly variable in both frequency and severity). Their pathophysiological mechanism is still elusive and is likely to be the result of the complex involvement of one or more mechanisms, like direct virus-induced skin damage, vasculitis-like reactions, and/or indirect injury as a consequence of a systemic inflammatory reaction.
Summary In this review, we presented and discussed clinical cases as examples of different cutaneous responses reported in some children with SARS-CoV-2 infection, differential diagnosis considerations, and a preliminary conceptual approach to some of their probable associated pathologic mechanisms.
Keywords COVID-19, pediatric • SARS-COV-2 • Purpuric lesion • Kawasaki-like • Pseudo-chilblain

This article is part of the Topical Collection on Allergic Skin Diseases
Introduction

Since the initial report in December 2019 of the first case of atypical pneumonia in Wuhan, China, caused by the new coronavirus, a variety of clinical manifestations have been reported, ranging from asymptomatic presentations—especially in children—to pulmonary or extrapulmonary symptoms fluctuating in severity. On February 11, 2020, the International Commission for Classification of Virus called this new coronavirus “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). On the same day, WHO gave the name “coronavirus disease 2019” (COVID-19) to the disease caused by SARS-CoV-2 (1). COVID-19 quickly disseminated to several regions of China and 197 countries and reached the status of pandemic on March 11, 2020 (2).

COVID-19 was noticed to be more prevalent in adults, and the proportion of confirmed cases in children at the beginning was very low. Reported data on COVID-19 in China showed that children under the age of 18 represented only 2.4% (1). A systematic review reported in May 2020 that in Italy 1.2% and in the USA 5% of the COVID cases were children (3). In Mexico by August 16, 2020, 18,278 (3.5%) cases had been reported in subjects up to 19 years of age, with a slight predominance of males (56%); more than 80% had mild symptoms (4). Recalcati first described dermatologic manifestations in 18 of 88 patients (20.4%) hospitalized with COVID-19, none within the pediatric age group. Skin lesions were present in eight patients at admission, while ten developed them during hospitalization. Cutaneous manifestations were erythematous rash (14 patients), widespread urticaria (three patients), and chickenpox-like vesicles (one patient) (5••). In April of this year, a multicenter study of children admitted to a pediatric intensive care unit in Great Britain with multisystemic inflammatory disease associated with SARS-CoV-2, reported that 44% presented dermatologic manifestations (rash), superposed on symptoms compatible with Kawasaki disease, toxic shock syndrome, hemophagocytic lymphohistiocytosis, and macrophage activation syndrome; clinical and laboratory studies were compatible with COVID-19 (6).

SARS-CoV-2 Invasion

The first step in any viral infection involves penetration of the viral particles into the cell. In the case of SARS-CoV-2, there are four hypothetic pathways involved. The most important one involves angiotensin-converting enzyme 2 (ACE2) (10, 11); see Fig. 1. Expression of ACE2 occurs in different cells: type-2 pneumocytes, enterocytes, macrophages, tongue, ciliated respiratory epithelium, clear cells, endothelium, proximal renal tubule, adipocytes, keratinocytes, and cells of the epithelium. Its expression increases with age, and it is higher in men (10). The cell distribution of ACE2 is very important, as it helps explain most of the symptoms (e.g., anosmia; taste disturbances; respiratory, cardiovascular, renal, and cutaneous symptoms) we see in patients with COVID-19 and it might contribute to the higher prevalence in men and in adults versus children (11•).

Related to the subject of this review, ACE2 is a membrane-bound receptor in cells of the basal epithelium and eccrine sweat glands. In normal skin, ACE2 is protected by the stratum corneum, but skin damage could allow the virus to reach its receptor. Eccrine glands are expressed in a large quantity in palms (12, 13).

The viral spike protein S of SARS-CoV-2 binds to ACE2 as a cellular receptor, and its affinity is 10–20-fold higher than that of SARS-CoV-1, augmenting its pathogenicity. This binding facilitates the entry of viral RNA assisted by the action of the protease TMPRSS2, which cuts the viral spike exposing subprotein S1 with the receptor-binding domain (RBD) (12, 14) (Fig. 2).

Immune Response to SARS-CoV-2

Once inside the cell, the genetic material and proteins are recognized by the innate immune system by both transmembrane and intracytoplasmic toll-like receptors (TLR3, TLR7, RIG-1, MDAS) that activate nuclear factors, inducing the production of pro-inflammatory cytokines. However, coronaviruses use different mechanisms to evade the immune system, creating a balance between viral elimination and permanence (10, 11, 15, 16). See Fig. 3.

The skin manifestations in COVID-19 are influenced by the abovementioned conditions. For example, the presence of ACE2 in the skin and the immune responses previously described; however, other mechanisms, like type III hypersensitivity reactions in the vascular endothelium, have also been described (16–18) resembling pathologic mechanisms of autoimmune diseases. In addition, cutaneous manifestations of SARS-CoV-2 infection can be induced by inflammatory cytokines produced by dermal dendritic cells, lymphocytes, mast cells, macrophages, and complement deposition (C5a, C4) on endothelial cells of dermal capillaries (16, 19, 20). Ultimately, the viral spike has the ability to activate complement, favoring more inflammatory damage (16, 17, 19, 21).
The different skin manifestations seen during this pandemic can be classified into 6 “main” categories and one miscellaneous subcategory, adjusted according to our findings in the pediatric age group (17); see Table 1.

Fig. 1 Hypothetic pathways involved in SARS-CoV-2 invasion into the host cell. Clathrin dependent, caveola dependent, flotillin dependent, and ACE2/TMPRSS2 dependent. Once the integrity of the cell membrane has been broken, viral RNA forms an endosome into the cell’s cytoplasm and uses the cellular machinery for viral replication and assembly.

Fig. 2 On the left-hand side, a schematic representation of the SARS-CoV-2 virus spike protein bound to the host cell (epidermis) via ACE2 and TMPRSS2. The spike protein contains two subunits, S1 and S2, containing the receptor-binding domain (RBD). The RBD is part of the S1 subunit, and the S2 subunit is for membrane fusion. The serine protease TMPRSS2 cleaves the spike glycoprotein between S1 and S2, which helps the virus to integrate into the cell membrane and allow it to enter the host cell. At the molecular level, the binding includes amino acids, hydrogens bonds, and electrostatic and hydrophobic interactions. On the right-hand side, crystallographic image of ACE2 and the spike protein and RBD within the S1 subunit binding to the receptor site of ACE2.
MIS-C multisystem inflammatory syndrome in children

Methods

The here presented review shall be divided into two sections. For each of the cutaneous manifestation, we present one of our cases, followed by a brief review of literature. To this end, we conducted a literature search in PubMed and Embase for original articles and case reports using the following mesh terms: [COVID-19 OR SARS-CoV-2] AND [cutaneous OR Dermatol*] with the age limit 0-18 years and publication dates January 1, 2020 till August 1, 2020. The language was restricted to English, Spanish, German, and Dutch. We also searched the Net for unindexed case presentations. Data extracted from the reviewed literature per cutaneous manifestation were the number of pediatric cases presented, start of the cutaneous lesion in relation to the start of the disease and relation to the clinical course, COVID-19 severity or laboratory findings, outcome, and biopsy findings (if presented). Detailed literature review tables with found pediatric cases listed one by one (age, clinical symptoms, etc.) can be found in the online repository (Efiles). The cutaneous manifestations shall be presented in order of frequency in the pediatric age group, which differs from the adult cutaneous COVID-19 cases.

Table 1  Skin manifestations in pediatric COVID-19 cases

| Manifestation |
|----------------|
| 1. Purpuric lesions (a) Pseudo-chilblain (b) Necrotic-acral ischemia, hemorrhagic macules, and cutaneous necrosis |
| 2. Morbilliform or maculopapular |
| 3. Erythema multiforme |
| 4. Urticarial |
| 5. Vesicular |
| 6. Kawasaki-like (typical or atypical; could be associated with MIS-C) |
| 7. Miscellaneous: livedo reticularis, maculopapular—pityriasis, rosea-like, erythema elevatum diutinum, enanthem, flexural rash |

Fig. 3  Immune response to SARS-CoV-2. The first barrier to stop viral spreading comes from the innate immune system. A balance is produced between elimination and survival of the virus. The inflammatory response induced by PAMP sensors, among others TLRs, stimulating the production of pro-inflammatory cytokines, some with chemoattractant properties, is fundamental. As such, natural killer cells (NK), macrophages (M), dendritic cells (DC), CD8 T cells, and cytokines like interferons (IFNs), TNFα, monocytic chemoattractant protein 1 (MCP1), and macrophage inflammatory protein (MIP) are part of this first barrier; during this first phase, the virus uses different ways of evasion. The balance between both determines which path shall be followed: the one of viral elimination brought on by a systemic inflammatory response (SIRS) ending with healing or the one of virus permanence that subsequently produces an over-activated immune response (the so-called immune hyperactivation, or erroneously referred to as the cytokine storm) advancing into a second SIRS, with activation of complement and the coagulation cascade, which, if not stopped, evolves into a multiorgan failure syndrome and death. An opportunistic infection can appear at this stage, activating SIRS with even more fatal consequences. The adaptive immune response is the second barrier and appears later with a powerful humoral and cellular immune response: IgM is the first antibody to appear followed by IgA and IgG. Specific IgG memory can last up to 3 months or more.
Cutaneous Manifestation 1: Purpuric Lesions, Mostly Acral (Including Pseudo-chilblain and Necrotic)

Clinical Case

AF alkaline phosphatase, Alb albumin, AST aspartate aminotransferase, ALT alanine aminotransferase, ERS erythrocyte sedimentation rate, GGT gamma glutamyl transpeptidase, PT prothrombin time

Review

One of the first reports of petechial skin lesions related to COVID-19 was in a Thai patient who was originally misdiagnosed as dengue, due to petechia, low platelet count, and general malaise; when respiratory problems appeared, a nasal swab was performed and a positive result of the RT-PCR for SARS-CoV-2 led to the correct diagnosis (22). Till now we have not found a description of such lesions in children with COVID-19.

Contrarily, acral lesions are common in children. They consist of erythematous-violaceous patches or purpuric spots with ill-defined borders (23–25) that are sometimes associated with hyperkeratotic areas (26) and that can evolve to bullae or digital edema (27). They appear in order of frequency in feet, in hands, or in both locations and are associated with a sensation of mild/moderate pain or itching. The different clinical patterns of acral lesions may be associated with other dermatoses and clinical manifestations.

In preliminary reports, the pseudo-chilblains have been prominently discussed, demonstrating that these usually affect young patients, lasting on average about 12 days, appearing at the end of the COVID-19 disease; these have been associated with a less severe illness in terms of hospital admission, pneumonia, admission to intensive care, or mortality. These can cause pain and/or itching in about a third of the cases (28).

In the literature review (see eFile), we found reports of a total of 228 children aged 2 to 17 years with acral lesions associated with the COVID-19 outbreak and without a personal or family history of rheumatological disorders or of similar, prior-onset lesions (with one exception) (29). Systemic manifestations in general were rare, and when they did occur, they preceded skin lesions by up to a month and could be symptoms of mild flu (23), abdominal discomfort (pain and diarrhea) (28), or generally low-grade—fever (24••). Dermoscopy presented with violaceous erythema, dilated capillaries, and areas of ischemia and hyperpigmentation (28), and biopsies, when performed, revealed non-specific changes except for the presence of fibrin clots in some cases (30, 31).

The resolution of the lesions occurred spontaneously in most of the patients without treatment within a maximum of 4–5 weeks after the onset of the dermatosis. In some cases, adjuvants such as steroids and topical antibiotics were used with similar outcome (32, 33).

In the beginning, the injuries were associated with acral friction dermatosis, due to changes in habits and behavior in the children (26) such as prolonged sessions of games on the floor, similar to the injuries that occur in ballet dancers and other sports with prolonged friction; however, the increase in dermatological consultations for this condition in the framework of the COVID-19 pandemic made us rethink the possibility of being a response produced by the virus.

Until now, the causal relationship of these lesions with COVID-19 has not been established and its pathophysiology has yet to be fully elucidated; of the 127 RT-PCR tests and 35 antibody tests for SARS-CoV-2, only 3 were found positive (1 RT-PCR, 1 IgG, 1 IgM). However, the increase in the appearance of these lesions in both children and adults in the framework of the COVID-19 pandemic is very striking and, also considering the fact that the performance of the tests is not completely solid, makes the need for close monitoring of these patients imperative, not ruling out an infectious process that is almost asymptomatic or in a recovery period.

Cutaneous Manifestation 2: Morbilliform or Maculopapular Rash

Clinical Case

Review

In adult series, a morbilliform rash seems to be the most common cutaneous manifestation of COVID-19 patients: an “erythematous rash” was reported in three-quarters of all dermatologic cases of the already referenced Italian series (5••) and in 47% of cases in the Spanish series (34). Although exact ages were not specified, all these cases seem to be in adults. Rarely pediatric case reports have been published. The largest series comes from Jordan: 5/61 hospitalized COVID-19-confirmed children presented a rash described as maculopapular and lacy and distributed on the arms, legs, and neck. In all children, COVID-19 was mild (35). Turkish pediatricians
Clinical case 1: Acral lesions in children

Legend: a) Erythematous violaceous patch in the auricle. b and c) Erythematous and infiltrated plaques associated with edema in palms and soles.

| COVID-19 confirmation | Yes, PCR SARS-CoV-2 positive. |
|-----------------------|-------------------------------|
| Sex and age:          | Female, 3 year-old, without history of rheumatic disease, lupus erythematosus, Raynaud’s phenomenon, acrocyanosis or previous history of chilblains. |
| Clinical course:      | Previously healthy, she began with abdominal pain, asthenia and arthralgia 10 days before consultation. Positive contact with confirmed COVID patient |
| Start of skin         | 24h previous patient began a disseminated dermatosis characterized by an erythematous violaceous patch in the auricle and erythematous and infiltrated plaques associated with edema in palms and soles, painful. |
| manifestation*        | |
| Lab findings:         | Hb 15.6g/dl, hematocrit 45.4%, leukocytes 17x10³/µl, lymphocytes 39.3%, lymphocyte count 6,630, neutrophils 47.7% (8,104), platelet count 422,000 x10³ µl, C-reactive protein 2.5 mg/L, total bilirubin 0.54mg/dL, PT 7g/dL, Alb 4.4g/dL, AF 162U/L, AST 17U/L, ALT 30U/L, DHL 440 U/L, GGT 28g/dl, procalcitonin 0.08 ng/ml, ERS12mm, D-Dimer 7337ng/ml, coagulation tests were normal. |
| Biopsy:               | Not done                       |
| Outcome:              | She was hospitalized for supplemental oxygen support, she received symptomatic treatment and prophylactic enoxaparin with complete remission of their skin lesions within three weeks and had no complications. |
published their experience with twenty hospitalized, COVID-19-confirmed pediatric cases. Three of them developed cutaneous manifestations, one of them probably due to hydroxychloroquine therapy. The second patient, an 11-year-old girl, presented an itchy maculopapular rash on her face and upper trunk on the day of admission, which lasted for 5 days. She was dismissed without further complications. The third patient, an 8-month-old child, presented a roseola-like erythema on her cheeks the day of admission. Klimach et al. in the UK reported on a 13-year-old boy with confirmed COVID-19 whose first clinical presentation was a rash, localized to the plantar aspects of the feet, axillae, and lower limbs. The morphology was predominantly maculopapular, but there were also some petechiae and annular lesions. Finally, Iranian physicians reported a 12-month-old infant presenting with fever and an aggressive maculopapular rash, which turned out to be COVID-19. Fortunately, the child survived the accompanying pneumonia and was discharged after 10 days.

Cutaneous Manifestation 3: Erythema Multiforme

Clinical Case

Review

In Spain, a retrospective study of general pediatric dermatology consultations from March 5 to April 15, 2020, reported erythema multiforme (EM)–like patterns in 37/122 (pediatric) patients (28.0%) aged 1–29 years (average 12.2 years). These lesions were characterized by rounded erythematous macules and vesicles that tend to coalesce, although compared with classical EM, individual lesions were described as smaller (< 1 cm diameter) and not usually presented with typical targetoid lesions; also, they were less widespread on 5.4% of the 37 patients presenting lesions at other sites of the body, including elbows, knees, and ears.

In another pediatric dermatology service, Torrelo et al. described in 4 out of 22 (18%) of COVID-19 cases dual lesions presenting simultaneously EM and chilblains. These lesions were located on the most common cutaneous sites of involvement of classical EM, but the histopathological features were not specific to EM (no necrotic keratinocytes).

A causal link of EM with COVID-19 was supported by the following features: (a) a positive SARS-CoV-2 PCR test in one patient; (b) a history of contact with a suspected COVID-19 case in one patient and mild respiratory symptoms some days before the skin lesions appeared in three cases; (c) occurrence during the peak period of incidence of COVID-19 in Madrid; (d) the presence of EM and chilblains in the same patients, appearing during an outbreak in an epidemic setting; and (e) the positive immunohistochemistry for SARS-CoV/SARS-CoV-2 spike protein in the endothelia and eccrine epithelia in the two biopsied cases.

Bapst et al. also reported a case that presented a multisystem inflammatory syndrome in children and adolescents (MIS-C) temporally related to COVID-19 associated with an erythema multiforme. This patient’s lesions were isolated round papular on his left shoulder with a central dark red zone surrounded by a pale ring of edema and an erythematous halo on the extreme periphery.

Cutaneous Manifestation 4: Urticaria

Clinical Case

Review

Urticaria is a condition manifested by wheals or hives, angioedema, or both. The hives can be of different shapes and vary in size from less than 5 mm to more than 10 cm. An evolution of less than 6 weeks is classified as acute urticaria; its prevalence in children varies between 4.5 and 15%. The most common cause of this form of urticaria is infectious, mostly respiratory infections. Other causes include medications and foods.

Acute urticaria has been considered a potential manifestation of COVID-19. According to different case reports and analysis of case series that have included children, urticaria could appear as one of the first manifestations of COVID-19, or it could appear at some point during the course of the disease, simultaneously with various signs and symptoms characteristic of COVID-19, with confirmed or strongly suspected SARS-CoV-2 infection. However, of all skin manifestations in children related to COVID-19, urticaria has been one of the least frequently reported ones (< 17%) (43–45).

The diagnosis of urticaria associated with COVID-19 is basically clinical. The duration of urticaria symptoms is generally short, varying from 6 to 7 days. Nowadays, when acute urticaria appears in a patient associated with fever, the diagnosis of COVID-19 should be considered.

Other forms of acute urticaria should be considered within the differential diagnosis of urticaria as a sign of COVID-19, including urticaria secondary to the
Morbilliform rash.

| Picture |
| --- |

**COVID-19 confirmation**  
Yes, PCR SARS-CoV-2 positive.

**Sex and age:**  
Female, 5 years.

**Clinical course:**  
Previously healthy, 6 days evolution with daily fever 38 - 40°C, asthenia and unwell being, conjunctival erythema, abdominal pain and dermatosis.

**Start of skin manifestation:**  
3rd day maculo-papular itch rash on neck, upper limbs and chest; and edema and erythema on palms symptomatic.

**Lab findings:**  
Hb: 12.2 g/dl, hematocrit: 37.1%, leukocyte9, 900 x10^3µl, neutrophil count: 8320, lymphocyte count: 1190, platelet count: 109.000 x10^3µl,  
C-reactive protein: 19.7 mg/L, globular sedimentation rate: 16”, D-dimer: 2477 ng/ml (normal range <500 ng/ml), ferritin: 558 ng/mL, fibrinogen: 654.3 mg/dL.  
Coagulation, urinalysis and liver function test normal.  
Echocardiogram normal.

**Biopsy:**  
Not performed.

**Outcome:**  
She received a single IV dose of immunoglobulin 2g/kg/dose, methylprednisolone 30 mg/kg/day, enoxaparin 1mg/kg/dose BID, ceftriaxone and amikacin for 14 days. She was discharged from the hospital for clinical improvement with follow-up in the outpatient clinic.

* in relation to the beginning of the first symptoms of COVID-19.
**Erythema multiforme**

| Picture |
|---------|

| COVID-19 confirmation | Yes, RT-PCR SARS-CoV-2 positive. |
|-----------------------|----------------------------------|
| Sex and age:          | Female, 6 years.                 |
| Clinical course:      | One-week evolution, beginning with vomiting of food content and stools of decreased consistency on the second day; daily fever of 38 to 39ºC, arthralgias, myalgias and on the day of his admission he presented hyaline rhinorhea, conjunctival erythema and dermatosis. |
| Start of skin manifestation*: | 7th day characterized by two annular spots, with erythematous border and pale central area, affecting abdomen and the thigh, asymptomatic; in addition, an erythematous pale spot with irregular limits, at the right lateral region of the thorax, asymptomatic also. |
| Lab findings:         | Hb: 11.5 g/dl, hematocrit: 35.1%, leukocyte 10,800 x10³µl, neutrophil count: 8,100, lymphocyte count: 1,940, platelet count: 322,000 x10³µl, C-reactive protein: 28.7 mg/L, globular sedimentation rate: 32", D-dimer: 1255 ng/ml (normal range <500 ng/ml), ferritin: 252 ng/mL. Coagulation, urinalysis and liver function test were normal. Echocardiogram and chest-CT normal. |
| Biopsy:               | Not performed.                   |
| Outcome:              | She received symptomatic treatment with complete remission of her skin. |

* in relation to the beginning of the first symptoms of COVID-19.
administration of drugs that can commonly be used in the treatment of patients with COVID-19, such as NSAIDs and antimicrobials (44).

The pathophysiology of urticaria associated with COVID-19 appears to be multifactorial. Proposed mechanisms include direct activation of mast cells by the virus, activation by complement secondary to deposition of antigen-antibody complexes, or mechanisms mediated by bradykinins or IL-6 (46).

The symptomatic treatment of urticaria, including that associated with COVID-19, is based on the administration of second-generation antihistamines, with which patients usually have a good clinical response (42–44).

Cutaneous Manifestation 5: Vesicular

Clinical Case

We have no clinical pediatric case with this manifestation. However, we would like to present the diagnostic dilemma we faced in our clinic. A middle-aged male was hospitalized due to respiratory failure secondary to COVID-19, confirmed by RT-PCR. On day 6, he developed generalized vesicular lesions predominantly on the trunk and fewer on the arms and face; of interest, there was no pruritus, and some ulcerative lesions even caused tenderness with a burning sensation of the area. The patient was managed with a colloidal bath to dry the lesions and deflazacort, responding quickly in 2 days, leaving only residual crusty brown lesions.

Within days, his wife brought us their 5-year-old daughter with a strongly pruritic, papulovesicular rash, and mild flu-like symptoms, frightened it might also be COVID-19. However, the typical varicelliform lesions of the girl, her clinical evolution, and a negative nasal swab finally led to the diagnosis of varicella. A week later, their son also presented a typical case of varicella (courtesy Dr. Rojo-Gutiérrez).

Review

The first case series published by Italian colleagues of cutaneous manifestations in 18 of 88 hospitalized patients included one case with varicella-like vesicles (5••). However, all were adults. In a second case series of 22 proven COVID-19 patients with varicelliform lesions and no history of new medications in the previous 15 days, the mean age of the patients was 60 years; but among them, there was one 8-year-old subject. Here the authors describe that lesions generally started at day 3 and lasted for about a week; strikingly, there was only mild/absent pruritus. Almost all had fever, and 3/22 patients finally died. Skin biopsy, taken in 7 patients, showed histological findings consistent with viral infection (25). Then, there was one case report of an 8-year-old girl with vesicular lesions (47).

Further into the pandemic, Spanish dermatologists published a paper on dermatologic patterns associated with SARS-CoV-2 infection, but without focusing on children. They describe that vesicular eruptions in COVID-19 are especially seen in the third to fourth decade of life in about 9% of their adult COVID-19 dermatologic cases. As opposed to varicella, the vesicles they described are monomorphic, small in some patients, but large and diffuse in others, filled with hemorrhagic material in some, mainly situated on the trunk. They describe the appearance of the lesions around day 10 of the disease, pruritic in two-thirds and related to an intermediate severity (48••).

Cutaneous Manifestation 6: Kawasaki-like and COVID-19 in Children

Clinical Case

To date, one of the most prominent mucocutaneous feature reported in children with COVID-19 is Kawasaki disease (KD), or more precisely KD-like. KD is a well-known cause of post-infectious vasculitis of medium-sized vessels with persistent fever, mucocutaneous symptoms, and systemic inflammation specifically presenting in the pediatric age group, mainly in small children (0–5-year-olds) (49). Its diagnostic criteria and treatment modalities are described elsewhere (50•). In the context of the novel pandemic, since the first published case of concurrent COVID-19 and KD in an adolescent (51), several other reports have emerged and special attention has been paid to this supposed clinical concurrence.

Although the pathogenesis of this condition is still unclear, coronavirus-induced disease has been previously reported as one of the known infections that can precede and probably trigger it (52). Given the great increase in worldwide cases of SARS-CoV-2, this fact alone can help to explain the supposed increase in cases of concurrent COVID-19 and KD. Nevertheless, there is still conflicting evidence whether KD is really more prevalent during the SARS-CoV-2 pandemic, firstly as KD may be underdiagnosed or undergo delayed treatment as a consequence of many parents’ hesitation or fear.
**Urticaria**

| Picture |
|---------|

Legend: Wheals and red-raised blanching rash plaques.

| COVID-19 confirmation | Yes, PCR SARS-CoV-2 positive |
|-----------------------|------------------------------|
| Sex and age:          | Male, 5-month-old            |
| Clinical course:      | Previously healthy, 24 hours of evolution with fever 38.4 °C and dry cough, azithromycin was indicated. Positive contact with confirmed COVID patient. |
| Start of skin         | At the same time the patient began disseminated dermatosis characterized by wheals and red-raised blanching rash plaques, azithromycin |
| manifestation*:       |                               |
| Lab findings:         | Hb 13g/dl, hematocrit 38.5, leukocyte 4.7x10^3µl, lymphocyte 75%, lymphocyte count 3,525, neutrophil count 470, platelets 171,000 x10^3µl, C-reactive protein 2.5 mg/L, total bilirubin0.4mg/dL, PT 6.2g/dL, Alb 4.4g/dL, FA 162U/L, AST 83U/L, ALT 93U/L, DHL 440 U/L, GGT 28g/dl, procalcitonin 0.08 ng/ml |
| Biopsy:               | Not done                     |
| Outcome:              | He was treated with paracetamol and antihistamines with improvement of the symptoms, vigilance in ambulatory clinic. |

* Biopsy: Not done.
to seek in-person consultations for their sick children in these times of sanitary contingency (53). Secondly, because most reported cases come from populations with typical low prevalence of KD (mainly Europe and the USA), while countries with higher KD incidence (i.e., Korea or Japan) have maintained their casuistic relatively stable (54).

More importantly, a high variability of clinical manifestations and outcomes has resulted in conflicting information to adequately categorize KD cases, since many patients have not presented a typical phenotypical picture, and there are increased reports of children with suspected or confirmed COVID-19 and symptoms fulfilling criteria for typical or atypical KD, but frequently associated with unusual age (i.e., older children and adolescents) and/or gastrointestinal symptoms (i.e., diarrhea, ileus); painful limb edema, sometimes overlapping with acute myocarditis associated with toxic shock syndrome and heart failure requiring hemodynamic management; and biochemical evidence of an unusually strong systemic inflammatory response, mostly with features of macrophage activation syndrome with raised serum ferritin.

Due to the almost simultaneous reports (and the lack of a global consensus), a number of semantic and clinical descriptions for apparently the same severe entity related to COVID-19 and symptoms fulfilling criteria for typical or atypical KD, but frequently associated with unusual age (i.e., older children and adolescents) and/or gastrointestinal symptoms (i.e., diarrhea, ileus); painful limb edema, sometimes overlapping with acute myocarditis associated with toxic shock syndrome and heart failure requiring hemodynamic management; and biochemical evidence of an unusually strong systemic inflammatory response, mostly with features of macrophage activation syndrome with raised serum ferritin.

Due to the almost simultaneous reports (and the lack of a global consensus), a number of semantic and clinical descriptions for apparently the same severe entity related to COVID-19 and KD-like symptoms can be found, like “hyperinflammatory shock,” “MIS-C,” “hyperinflammatory syndrome with multiorgan involvement,” “pediatric inflammatory multisystem syndrome (PIMS),” “Kawasaki-like syndrome,” or “Kawasaki-like disease” (54). Case definitions are still a work in progress, and although both CDC and the WHO have published similar preliminary diagnostic criteria for suspected cases, they are not completely equivalent, as the CDC criteria are slightly more inclusive, with a broader range of age and a larger list of inflammatory reactants to be considered (Table 2) (55, 56).

As far as we can ascertain, two European case series (summarizing 18 patients, mean age 7.5 years) of KD-like clinical features plus shock, high inflammatory indices, and/or acute cardiologic involvement (mainly myocardial) have been published (57, 58). In both, despite having a serious clinical picture, most patients did not have severe respiratory symptoms, which is unusual in COVID-19. Most patients fully recovered after intensive management complemented with prompt treatment with intravenous immunoglobulin (a therapeutic modality with strong anti-inflammatory properties approved for both KD and severe acute myocarditis). A much bigger, population-based American study of 186 previously healthy children with MIS-C associated with SARS-CoV-2 infection (mean age 8.3 years) reported similar results. In this study, mucocutaneous features were present in 74% of the cases (n = 137) (59).

Still, there is high uncertainty over the real concurrency, and thus causal relationship, between KD and COVID-19. Based on the above, there is increasing epidemiologic, clinical, and laboratory evidence to support the concept of a new hyperinflammatory syndrome separated from KD concurrent with SARS-CoV-2 infection in children. Regardless of the name given to this newly reported condition, the challenge for future studies shall be to understand its pathophysiology, to find consensus to better define its clinical characteristics and biochemical indicators, but mostly to define the best treatment options.

**Differential Diagnosis**

A meticulous examination and clinical correlation of dermatologic manifestations and suspected COVID-19 in the pediatric population is needed in order to distinguish similarities between conditions that can be easily misdiagnosed.

In Table 3, we include a summary of diagnosis that need to be taken into account according to the type of dermatological lesion.

**Pathophysiology of Cutaneous Lesions in COVID-19**

It seems that COVID-19 can express a plethora of different symptoms and, apart from the respiratory system, can affect other organs including the skin (17•). As many patients have been treated with medication, before skin lesions appear, it is often impossible to define if the lesions are caused by the infection or due to drug reactions.

The mechanisms by which infection with SARS-CoV-2 could cause skin lesions can fundamentally be divided into three categories:

I. **Vasculitis** (69)

II. **Coagulopathy**

III. **Direct viral infection of skin cells**

These shall be reviewed in more detail below.

**COVID-19 and Vasculitis**

It is interesting that the majority of the cutaneous manifestations related to COVID-19 can also be present with different forms of vasculitis (70); mucocutaneous changes commonly related to Kawasaki disease (58); urticaria-like lesions (71); erythematous maculopapular, vesicular, or chickenpox-like rashes (37•); livedo reticularis (72); erythema multiforme-like (69); chilblains (73); and petechiae (74). Current
Clinical case: **MIS-C**

**Pictures: a, b, c, d**

| Clinical case: | Bilateral non-purulent conjunctivitis |
|----------------|--------------------------------------|
| COVID-19 confirmation | Yes, PCR SARS-CoV-2 positive.
| Sex and age: | Female, 10-year-old |
| Clinical course: | Previously healthy, she began with fever 39°C, asthenia and unwell being 4 days before consultation, diarrhea and vomiting. Positive contact with confirmed COVID patient |
| Start of skin manifestation*: | 24h previous patient began a disseminated dermatosis characterized by a maculo-papular rash affecting trunk and extremities. |
| Lab findings: | Hb 10.5 g/dl, hematocrit 31.7 %, leukocyte 5,800 x10^3µl, lymphocyte count 350, immature neutrophils 42%, platelets 92,000 x10^3µl, C-reactive protein 18.6mg/L, globular sedimentation rate 20mm, D-Dimer 17,099ng/ml, fibrinogen 583 mg/dL. |
| Echocardiogram | Mitral and pulmonary insufficiency, normal ventricular function |
| Biopsy: | Not done |
| Outcome: | She was hospitalized for mechanic ventilation, she received a single dose of immunoglobulin IV 2g/kg/dose, methylprednisolone, enoxaparin 1mg/kg/dose every 12 hours, ceftriaxone and amikacin for 14 days, the patient developed a cholestatic syndrome and received ursodeoxycholic acid, she was discharged from the hospital for clinical improvement and with follow-up in the outpatient clinic. |
pathophysiological approaches to this disease indicate in fact that vasculitis could be a major pathological mechanism (16).

To date, it is not yet clear if the cutaneous features of the disease are due to direct viral skin affection that cause these changes or if they are secondary complications or a combination of the two (74). Currently, there are not enough solid data to determine the mechanisms by which this coronavirus causes vasculitis, but we can present some speculations, extrapolating observations from other organs. Firstly, it appears that the virus can invade endothelial cells directly (75**), as its receptor, ACE2, is widely present on their surface (76). Biopsy-confirmed endotheliitis has been reported recently in kidney, cardiac, and intestinal tissue, demonstrating the presence of viral elements within endothelial cells and diffuse endothelial inflammation (75**).

Secondly, circulating immune complexes can lead to (potentially life-threatening) lymphocytic vasculitis (77). A third probable mechanism by which SARS-CoV-2 can cause skin lesions could be by activation of the keratinocytes through stimulated Langerhans cells, as a consequence of the inflammatory process (78).

**Examples of Pathologic Pattern of Cutaneous Lesions Associated with Vasculitis in Patients with COVID-19**

Reports of cutaneous biopsies of COVID-19 positive patients with skin symptoms have taught us that some injury usually takes place within both shallow and deeper skin vessels, inducing lesions commonly seen in vasculitis, like nodules, livedo reticularis, or ulcerations (70). However, there is still great variability in such biopsy findings. For example, tissue reports of a COVID-19-associated exanthematous and hemorrhagic rash showed telangiectatic blood vessels, along with epidermal lymphocytic perivascular infiltrates, Langerhans cell proliferation, and dermal eosinophilic infiltration, while hemorrhagic exanthema lesions showed microthrombi (see below) (78). In another case, an erythema multiforme lesion showed a perivascular and interstitial lymphocyte infiltrate, as well as dermal vasodilation with neutrophils filling and extravasation of red blood cells. Also, this case coexisted with pseudo-vesicles and enanthema, which helped to rule out a drug reaction (69).

Such variability in infiltrates of different cells and pathologic patterns are currently not fully understood, so further microscopic exploration and immuno-histopathologic description of lesions is required to enhance our knowledge about the immunopathologic mechanisms.

The acute urticarial skin lesions described with COVID-19 usually persist for over 24 h and as such do not fulfill the description of the typical urticaria lesions. They are usually an early feature of the disease (79), but they also may appear in the late phases (80). They do not have the typical histopathological features either (80), and clinically, they behave more like urticarial vasculitis (6).

**COVID-19 and Microthrombi**

COVID-19-associated coagulopathy (CAC) refers to a state of hypercoagulability demonstrated not only in several patients, especially in the critically ill, where it resembles disseminated intravascular coagulopathy (DIC), but also in mild cases. This has been related to (81)

1. Augmented factor VIII
2. Augmented fibrinogen
3. Circulating prothrombotic microparticles
4. Neutrophil extracellular traps (NETs)
5. Hyperviscosity of plasma
6. Release of the von Willebrand factor by endothelial injury

From cutaneous biopsy and autopsy samples from 3 individuals with severe COVID-19, a pauci-inflammatory, complement-mediated microthrombotic pattern was documented in the skin, with retiform and purpuric lesions and C5b-9 and C4d deposition in samples from both cutaneous lesions and normal-appearing skin (19).

Accordingly, another mechanism of skin damage is related to the formation of microthrombi. These can develop in situ, or there is also a possibility that microthrombi detached from other organs cause a reduced blood perfusion to the microvasculature of the skin (causing the appearance of livedo reticularis) or as a complication from disseminated intravascular coagulation. All these mechanisms can lead to different skin manifestations (72).

**Direct Viral Infection of Skin Cells**

Still another proposed etiology for rash in patients with COVID-19 has been direct invasion of cutaneous cells by the virus, based on observed high concentrations of lymphocytes without eosinophils, papillary dermal edema, epidermal spongiosis, and lympho-histiocytic infiltrates (74).

The histopathology of the skin specimens in some COVID-19 patients shows the classic dyskeratotic cells and ballooning multinucleated cells and sparse necrotic keratinocytes with lymphocytic satelliteitis (78). These overlapping features mimic a viral infection, especially by Herpesviridae.

Histopathological changes at an early stage of an exanthema involving the trunk and limbs showed in the upper dermis diffuse telangiectatic small blood vessels with no other peculiar features; in a second biopsy, nests of Langerhans cells within the epidermis were the unique clue in this stage.
When purpuric maculo-papulo-vesicular rash developed, histological findings showed perivascular spongiotic dermatitis with exocytosis along with a large nest of Langerhans cells and a dense perivascular lymphocytic infiltration, eosinophil rich, around the swollen blood vessels with extravasated erythrocytes (78).

Among skin pathologies in which a virus is implicated, we can see various types of manifestations in the cutaneous area involved. Frequently, it is merely an exanthema indicating a hematogenous spreading of the virus through the cutaneous vascular system. The next step could create activation of the immune system with mobilization of lymphocytes and Langerhans cells patrolling that run through the skin-lymph node path. If the virus swarm induces the creation of immune complexes, this can lead CD4+ T helper cells to produce cytokines, like IL-1, IFN-γ, and TNF-α, and to recruit eosinophils, CD8+ cytotoxic T cells, B cells, and natural killer (NK) cells, creating lymphocytic thrombophilic arteritis (82). There are underhanded viral attacks that probably induce a modification in the structure of the keratinocytes that then can be destroyed by cytotoxic lymphocytes, almost resembling the well-known ancient trick of the “Trojan horse”(78).

### Conclusion

In this review, we presented and discussed clinical cases as examples of different cutaneous responses previously reported in some children with SARS-CoV-2 infection, which, to date, are poorly categorized due the high heterogeneity among different case series, in both frequency and severity. As new studies emerge and a better clinical description of these cutaneous symptoms is defined and their causal mechanism is better understood, a clearer framework will be available to properly interpret them for diagnostic, therapeutic, and prognostic purposes. Until then, physicians should be very careful in evaluating skin reactions in children with suspected coronavirus-induced disease and when possible collaborate in enhancing our understanding by publishing them.

### Compliance with Ethicals Standards

**Conflict of Interest**

The authors declare no conflicts of interest relevant to this manuscript.

**Human and Animal Rights and Informed Consent**

This article does not contain any studies with human or animal subjects performed by any of the authors.

---

**Table 2** CDC and WHO preliminary case definition criteria for the multisystem inflammatory syndrome (or disorder) in children

| Centers for Disease Control and Prevention (CDC) (55••) | World Health Organization (56) |
|--------------------------------------------------------|--------------------------------|
| An individual aged < 21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological) | Children and adolescents 0–19 years of age with fever ≥ 3 days |
| And No alternative plausible diagnoses | And two of the following: |
| And Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test or COVID-19 exposure within the 4 weeks prior to the onset of symptoms | 1. Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet) |
| | 2. Hypotension or shock |
| | 3. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated troponin/NT-proBNP) |
| | 4. Evidence of coagulopathy (by PT, PTT, elevated D-dimers) |
| | 5. Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain) |
| | Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitin |
| | And No other obvious microbial cause of inflammation, including bacterial sepsis and staphylococcal or streptococcal shock syndromes |
| | And Evidence of COVID-19 (RT-PCR, antigen test, or serology positive) or likely contact with patients with COVID-19 |

1 Fever ≥ 38.0 °C for ≥ 24 h or report of subjective fever lasting ≥ 24 h

2 Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes, and low albumin
### Table 3  Main differential diagnosis according to dermatological lesions (60–68)

| Clinical symptoms and signs | Laboratory findings apart from RT-PCR (−) | Comments |
|----------------------------|------------------------------------------|----------|
| Morbilliform rash          |                                         |          |
| Measles                    | -Malaise, anorexia, conjunctivitis, coryza, and cough | Serologic confirmation and/or PCR despite report of vaccination |
|                            | -Koplik spots                            |          |
|                            | -High-grade fever                         |          |
|                            | -Maculopapular rash that spreads cephalocaudally |          |
|                            | -Edema in eyelids                         |          |
|                            | -Fever that exceed 40 °C (104 °F) during 3–5 days resolves followed by rash | Seldom needed |
|                            | -Children are active and well             |          |
|                            | -Associated palpebral edema               |          |
|                            | -Maculopapular rash                       |          |
|                            | -Scarlet fever-like                      |          |
|                            | -Red and bright petechiae                 |          |
|                            | -Severe arthralgia                       |          |
|                            | -Bullous and vasculitis skin lesions associated with condition aggravated (chikungunya) |          |
|                            | -CBC with leukopenia and neutropenia      |          |
|                            | -Present in endemic areas                 |          |
|                            | -RT-PCR/serological testing               |          |
| Roseola infantum (exanthem subitum) |                                         |          |
|                            | -Edema in eyelids                         |          |
|                            | -Fever that exceed 40 °C (104 °F) during 3–5 days resolves followed by rash | Seldom needed |
|                            | -Children are active and well             |          |
|                            | -Associated palpebral edema               |          |
|                            | -Maculopapular rash                       |          |
|                            | -Scarlet fever-like                      |          |
|                            | -Red and bright petechiae                 |          |
|                            | -Severe arthralgia                       |          |
|                            | -Bullous and vasculitis skin lesions associated with condition aggravated (chikungunya) |          |
|                            | -CBC with leukopenia and neutropenia      |          |
|                            | -Present in endemic areas                 |          |
|                            | -RT-PCR/serological testing               |          |
| Erythema infectiosum       |                                         |          |
|                            | -Slapped cheeks followed by erythematous maculopapular rash in arms and trunk with reticular pattern |          |
|                            | -Associated palpebral edema               |          |
|                            | -Maculopapular rash                       |          |
|                            | -Scarlet fever-like                      |          |
|                            | -Red and bright petechiae                 |          |
|                            | -Severe arthralgia                       |          |
|                            | -Bullous and vasculitis skin lesions associated with condition aggravated (chikungunya) |          |
|                            | -CBC with leukopenia and neutropenia      |          |
|                            | -Present in endemic areas                 |          |
|                            | -RT-PCR/serological testing               |          |
| Dengue/Zika/chikungunya    |                                         |          |
|                            | -CBC with leukopenia and neutropenia      |          |
|                            | -Present in endemic areas                 |          |
|                            | -RT-PCR/serological testing               |          |
| Chilblain                  |                                         |          |
| Meningococcemia (60)       | -Critically ill patient                   |          |
|                            | -Sudden onset of skin lesions            |          |
|                            | -Meningismus and impaired consciousness   |          |
|                            | -CBC with leukocytosis and neutrophilia   | Considered if the patient (a) Is not vaccinated (b) Has a complement pathway defect (c) Takes drugs that interfere with the complement pathway |
| Henoch-Schönlein*          | -Moderate-severe abdominal pain           |          |
| Hematuria                  | -Normal CBC                              |          |
|                            | -Renal involvement                       |          |
| Hemorrhagic edema          | -Not needed                              | History of infection, drug-exposure or active immunization in the previous days |
|                            | -Low-grade fever, non-toxic appearance   |          |
|                            | -Target-like, macular to purpuric plaques in face, ear lobes and extremities; non-pitting edema of the distal extremities |          |
| Acral                      | -Local trauma history                    |          |
| Trauma                     | -Excessive sweating of the feet or exposure to water and detersgens |          |
| Contact dermatitis         | -Infective endocarditis related, cardiac surgery, or IV drug abuse |          |
| Septic emboli              |                                         |          |
| Erythema multiforme–like   | -Exclusion of Herpesviridae family and Mycoplasma pneumoniae |          |
| Acute urticaria            | -Repeated symptoms on re-exposure        |          |
| Food or drug allergy       | -Presence of specific IgE                |          |
| Viral infections           | -Positive challenge test                 |          |
|                            | -None                                    |          |
| Chickenpox–like rashes     | -Tzanck test and varicella zoster PCR can be used to make differential diagnosis (61) |          |
| Chickenpox                 |                                         |          |
|                            | -Macules, papules, vesicles, and crusts at the same time |          |
|                            | -Lesions start on hairy skin             |          |
|                            | -Lesions appear from periphery to the center |          |
|                            | -Mucous membranes may be involved        |          |
|                            | -Appears in crops                        |          |
| Multisystem inflammatory syndrome in children (MIS-C) | -Cardiovascular findings are not part of the diagnostic criteria |          |
| Kawasaki                   | -No typical order of appearance          |          |
|                            | -Fever and cervical adenopathy           |          |
|                            | -Conjunctivitis, mucositis, polymorphous rash |          |
|                            | -Extremity indurated edema is the last manifestation |          |

*Alberti-Violetti S, Berti E, Marzano AV. Cutaneous and systemic vasculitides in dermatology: a histological perspective. G Ital Dermatol Venereol. 2018;153(2):185-193. doi:10.23736/S0392-0488.18.05886-8*
References

Papers of particular interest, published recently, have been highlighted as:

• Of importance
• Of major importance

1. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol. 2020;92(7):747–54.
2. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020: World Health Organization; 2020 [Available from: https://www.who.int/dghs/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-%2D%2D11-march-2020.]
3. Ludvigsson JF. Children are unlikely to be the main drivers of the COVID-19 pandemic - a systematic review. Acta Paediatr. 2020;109(8):1525–30.
4. DGE. Covid-19 México: CONACYT - CentroGeo - GeoInt - DataLab; 2020 [updated August 16th, 2020. Available from: https://coronavirus.gob.mx/datos/. Official database of the Mexican government on health statistics related to COVID-19, sorted by age group.
5. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020. First publication on dermatologic manifestations related to COVID-19 (in all adults).
6. Davis MDP, van der Hilst JCH. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract. 2018;6(4):1162–70.
7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020.
9. Lu X, Xiang Y, Du H, Wing-Kin Wong G. SARS-CoV-2 infection in children - understanding the immune responses and controlling the pan-demic. Pediatr Allergy Immunol. 2020. * Comprehensive review of COVID-19 in children, specifically focusing on the immune responses.
10. Glebov OO. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. FEBS J. 2020.
11. Matteiardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol. 2020. Very comprehensive review of immunological changes secondary to SARS-CoV-2 infection, linking them to diagnosis and prevention. No special note on children.
12. Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020.
13. Muus C, Luecken M, Eraslan G, Waghray A, Heimberg G, Sikkema L, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv. 2020: 049254.
14. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020.
15. Chang, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, et al. Persistent viral presence determines the clinical course of the disease in COVID-19. J Allergy Clin Immunol Pract. 2020;8(8):2585-91 e1.
16. Criado PR, Abdalla BMZ, de Assis IC. van Blaricum de Graaff Mello C, Caputo GC, Vieira IC. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res. 2020;69(8):745–56.
17. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrwah TS, et al. Extrapolmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–32. Review of the extrapolmonary organ-specific pathophysiology and linking this to the presentations and management considerations in patients with COVID-19.
18. Jose RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 2014;69(2):190–2.
19. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
20. Criado PR, de Carvalho FY, Ayabe LA, Brandt HR, Romiti RM, Maruta CW. Urticaria and demographism in patients with adult-onset Still’s disease. Rheumatol Int. 2012;32(8):2551–5.
21. Llamas-Velasco M, Munoz-Hernandez P, Lazaro-Gonzalez J, Reolid-Perez A, Abad-Santamaria B, Fraga J, et al. Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19. Br J Dermatol. 2020.
22. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82(5):e177.
23. Colonna C, Monzani NA, Rocchi A, Gianottti R, Boggio F, Gelmetti C. Chilblain-like lesions in children following suspected COVID-19 infection. Pediatr Dermatol. 2020;37(3):437–40.
24. Colonna C, Spinelli F, Monzani NA, Ceriotti F, Gelmetti C. Chilblains in children in the time of COVID-19: new evidence with serology assay. Pediatr Dermatol. 2020. Chilblain lesions in children seemingly have no direct relation to COVID-19 infection.
25. Colonna C, Genovese G, Monzani NA, Picca M, Boggio F, Gianottti R, et al. Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic. J Am Acad Dermatol. 2020.
26. Bodak N, Chiaverini C, Barbarot S. COVID-19 lockdown induced acral dermatos in children. J Eur Acad Dermatol Venereol. 2020.
27. Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A, Provero MC, et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol. 2020;34(8):e346–e7.
28. Andina D, Noguera-Morel L, Bascua-Arribas M, Guitero-Tristan J, Alonso-Cadenas JA, Escalada-Pellittero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406–11.
29. Garcia-Lara G, Linares-Gonzalez L, Rodenas-Herranz T, Ruiz-Villaverde R. Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak. Dermatol Ther. 2020; e13516.
30. El Hachem M, Diociattui A, Concato C, Carsetti R, Carnevale C, Ciofi Degli Atti M, et al. A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. J Eur Acad Dermatol Venereol. 2020.
31. Roca-Gines J, Torres-Navarro I, Sanchez-Arraez J, Abril-Perez C, Sabalza-Baztan O, Pardo-Granell S, et al. Assessment of acute acral dermatosis in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406–11.
32. Garcia-Lara G, Linares-Gonzalez L, Rodenas-Herranz T, Ruiz-Villaverde R. Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak. Dermatol Ther. 2020; e13516.
33. Mastrolonardo M, Romita P, Bonifazi E, Giuffrida R, Lotti T, Foti C, et al. The management of the outbreak of acral skin manifestations in asymptomatic children during COVID-19 era. Dermatol Ther. 2020; e13617.
34. Catala A, Galvan-Casas C, Carretero-Hernandez G, Rodriguez-Jimenez P, Fernandez-Nieto D, Rodriguez-Villa A, et al. Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study. Dermatol Ther. 2020.

35. Kilani MM, Odeh MM, Shahlabi M, Al Qassieh R, Al-Tamimi M. Clinical and laboratory characteristics of SARS-CoV2-infected paediatric patients in Jordan: serial RT-PCR testing until discharge. Paediatr Int Child Health. 2020;1:10.

36. Bursal Duranaz B, Yozgat CY, Yozgat Y, Turel O. Appearance of skin rash in pediatric patients with COVID-19: three case presentations. Dermatol Ther. 2020:e13594. Rash can be a presenting sign of COVID-19 in children.

37. Klimach A, Evans J, Stevens J, Creasey N. Rash as a presenting complaint in a child with COVID-19. Pediatr Dermatol. 2020. Rash can be a presenting sign of COVID-19 in children.

38. Navaeiifar MR, Poudineh Ghazaghetti M, Shahbaznejad L, Rouhanizadeh H, Abutalebi M, Ranjarbar Varandi M, et al. Fever with rash is one of the first presentations of COVID-19 in children: a case report. Int Med Case Rep J. 2020;13:335–40.

39. Fernández-Nieto D, Jimenez-Cahué J, Suarez-Valle A, Moreno-Argónnes OM, Saceda-Corrado A, Arana-Raja A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020;83(1):e61–e3.

40. Torrelo A, Andina D, Santonja C, Noguea-Morel L, Bascunas-Arribas M, Gaitero-Tristan J, et al. Erythema multiforme-like lesions in children and COVID-19. Pediatr Dermatol. 2020;37(3):442–6.

41. Bapat T, Romano F, Muller M, Rohr M. Special dermatological presentation of paediatric multisystem inflammatory syndrome related to COVID-19: erythema multiforme. BMJ Case Report. 2020;10(6).

42. Larenas-Linnemann D, Medina-Avalos MA, Ortega-Martell JA, Gaitero-Tristan J, et al. Multisystem inflammatory syndrome in children and COVID-19. Pediatr Dermatol. 2020;37(3):435–8.

43. Genovese G, Colonna C, Marzano AV. Vascular-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatr Dermatol. 2020;37(3):435–6.

44. Galvan Casas C, Catala A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. Consensus report of Spanish dermatologists related to classification of cutaneous manifestations of COVID-19. No special focus on children, though.

45. Xu S, Chen M, Weng J. COVID-19 and Kawasaki disease in children. Pharmacol Res. 2020;159:104951.

46. Harsahshe AS, Dahdah N, Newburger JW, Portman MA, Piram M, Tulloh R, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr 2020;222:261–2.

47. Kone-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2).

48. Gupta-Malhotra M, Rao PS. Current perspectives on Kawasaki disease. Indian J Pediatr. 2005;72(7):621–9.

49. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhamms MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.

50. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403.

51. Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Rash can be a presenting sign of COVID-19 in children.

52. Verdone L, Magzza A, Gervasoni A, Martelli L, Ruggeri M, Ciuflendra M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–8.

53. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in children and adolescents. N Engl J Med. 2020;383(4):334–46.

54. Kone-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2).

55. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8. One of the first reports of MIS-C in children with COVID-19.

56. Hubschen JM, Arashiro T, Arima Y, Matsui T, Shimada T, Kinoshita H, et al. Dengue sentinel traveler surveillance: monthly and yearly notification trends among Japanese travelers, 2006-2014. PLoS Negl Trop Dis. 2016;10(8):e0004924.

57. Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease in patients with presumed meningococcal disease. Eur J Clin Microbiol Infect Dis. 2020;39(11):158.

58. Theocharis P. Hyperinflammatory shock in children during the COVID-19 pandemic. Lancet. 2020;395(10237):1607–8.

59. Hubschen JM, Arashiro T, Arima Y, Matsui T, Shimada T, Kinoshita H, et al. Dengue sentinel traveler surveillance: monthly and yearly notification trends among Japanese travelers, 2006-2014. PLoS Negl Trop Dis. 2016;10(8):e0004924.

60. Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Chikungunya. epidemiology, pathogenesis, clinical features, management, and prevention Infect Dis Clin North Am. 2019;33(4):1003–25.

61. Morey-Olive M, Espiau M, Mercadal-Halty M, Lera-Carballe L, Garcia-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). In: An Pediatr (Engl Ed); 2020.

62. Hubschen JM, Bork SM, Brown KE, Mankertz A, Santibanez S, Chikungunya. epidemiology, pathogenesis, clinical features, management, and prevention Infect Dis Clin North Am. 2019;33(4):1003–25.

63.ness of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr 2020;222:261–2.
Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol. 2020.

70. Frumholtz L, Laurent-Roussel S, Lipsker D, Terrier B. Cutaneous vasculitis: review on diagnosis and clinicopathologic correlations. Clin Rev Allergy Immunol. 2020.

71. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(6):e244–e5.

72. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700.

73. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020;34(7):e291–e3.

74. Gottlieb M, Long B. Dermatologic manifestations and complications of COVID-19. Am J Emerg Med. 2020;38(9):1715–21.

75. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. Biopsy-based demonstration of endothelial cell infection by SARS-CoV-2.

76. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10.

77. Roncati L, Ligabue G, Fabbiani L, Malagoli C, Gallo G, Lusenti B, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487.

78. Gianotti R, Zerbi P, Dodiuk-Gad RP. Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Dermatol Sci. 2020;98(2):141–3.

79. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(7):e300–e1.

80. Rodriguez-Jimenez P, Chicharro P, De Argüa D, Munoz-Hernandez P, Llamas-Velasco M. Urticaria-like lesions in COVID-19 patients are not really urticaria - a case with clinicopathological correlation. J Eur Acad Dermatol Venereol. 2020.

81. Cuker A, Peyvandi M. Coronavirus disease 2019 (COVID-19): hypercoagulability: Wolters Kluwer; 2020. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-hypercoagulability

82. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020;34(7):e306–e7.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Désirée Larenas-Linnemann1,2, Jorge Luna-Pech3, Elsy M. Navarrete-Rodríguez4, Noel Rodríguez-Pérez5, Alfredo Arias-Cruz6, María Virginia Blandón-Vijil7, Blanca E. Del Rio-Navarro4, Alan Estrada-Cardona8, Ernesto Onuma-Takane7, Cesar Fireth Pozo-Beltrán9, Adriana María Valencia-Herrera10, Francisco Ignacio Ortiz-Aldana11, Mirna Eréndira Toledo-Bahena10

1 Médica Sur Fundación Clínica y Hospital, Mexico City, Mexico
2 Hospital Médica Sur, Torre 2, cons. Puente de piedra 150, T2-602 Toriello-Guerra; delegación Tlalpan, Mexico City, Mexico
3 Departamento de Disciplinas Filosóficas Metodológicas e Instrumentales, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
4 Servicio de Alergia e Inmunología Clínica, Hospital Infantil de Mexico Federico Gómez, Mexico City, Mexico
5 Consulta Privada, Universidad Autónoma de Tamaulipas, Matamoros, Tamaulipas, Mexico
6 Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
7 Consulta Privada, Hospital Médica Sur, Mexico City., Mexico
8 Consulta Privada, Grupo COSTAMED, Playa del Carmen, Quintana Roo, Mexico
9 Subdirección de Enseñanza e Investigación, Hospital General de Especialidades Juan María Salvatierra, La Paz, Baja California Sur, Mexico
10 Servicio de Dermatología, Hospital Infantil de Mexico Federico Gómez, Mexico City, Mexico
11 ALERGO-ASMA de México, Irapuato, Guanajuato, Mexico